Ordinary Reweighting | Several Solactive Indices | Effective Date 2nd October 2023
RBC Biotech Opportunities GTR Index:
In the ordinary reweighting, the following composition will be implemented effective open 02.10.2023:
ABBVIE INC |
ALNYLAM PHARMACEUTICALS INC |
BIOGEN INC |
BIOMARIN PHARMACEUTICAL INC |
ELI LILLY & CO |
GILEAD SCIENCES INC |
INCYTE CORP |
INTRA-CELLULAR THERAPIES INC |
KARUNA THERAPEUTICS INC |
SAREPTA THERAPEUTICS INC |
SEAGEN INC |
RBC Biotech Opportunities GTR Index Series 2:
In the ordinary weighting, the following composition will be implemented effective open 02.10.2023:
ABBVIE INC |
AGIOS PHARMACEUTICALS INC |
ALNYLAM PHARMACEUTICALS INC |
AMGEN INC |
BIOGEN INC |
ELI LILLY & CO |
GILEAD SCIENCES INC |
INCYTE CORP |
INTRA-CELLULAR THERAPIES INC |
KARUNA THERAPEUTICS INC |
PACIRA BIOSCIENCES INC |
SAREPTA THERAPEUTICS INC |
SEAGEN INC |
XENON PHARMACEUTICALS INC |
RBC Global Low Carbon Transition GTR Index:
In the ordinary weighting, the following composition will be implemented effective open 02.10.2023:
AIR LIQUIDE SA |
ANALOG DEVICES INC |
ANGLO AMERICAN PLC |
APTIV PLC |
ASML HOLDING NV |
ASSA ABLOY AB CLASS B |
DEERE & CO |
ENEL SPA |
IBERDROLA SA |
NATIONAL GRID PLC |
NIDEC CORP ORD |
ORSTED A/S |
RWE AG |
SCHNEIDER ELECTRIC SE |
SIEMENS AG |
SMURFIT KAPPA GROUP PLC |
UNION PACIFIC CORP |
XYLEM INC |